The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
14 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $7,862,067 in first-year total cost, median $571,674.
Most frequent study sections
- Mechanisms of Cancer Therapeutics - 1 Study Section[MCT1]3
- Clinical Oncology Study Section[CONC]2
- Special Emphasis Panel[ZRG1 OTC1-M (80)]2
- Cancer Genetics Study Section[CG]1
- Cancer Molecular Pathobiology Study Section[CAMP]1
Most frequent institutions
- CEDARS-SINAI MEDICAL CENTER3
- ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI2
- ALBERT EINSTEIN COLLEGE OF MEDICINE1
- DANA-FARBER CANCER INST1
- DARTMOUTH-HITCHCOCK CLINIC1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2023 | HLA-E and NKG2A define a novel immune checkpoint axis in non-muscle-invasive bladder cancer1R01CA269954-01A1 | HOROWITZ, AMIRSFAKIANOS, JOHN | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $686,087 | CONC |
| 2023 | Transcriptional-translational conflict in bladder epithelial homeostasis and cancer1R01CA276308-01 | HSIEH, ANDREW CALEB | FRED HUTCHINSON CANCER CENTER, WA | $588,061 | CAMP |
| 2023 | A New Immune Checkpoint Pathway in Human Bladder Cancer1R01CA262132-01A1 | ZANG, XINGXING | ALBERT EINSTEIN COLLEGE OF MEDICINE, NY | $545,478 | ZRG1 |
| 2022 | Bladder cancer PD-L1 control of homologous recombination: Basic mechanisms applied to novel treatments1R01CA268641-01A1 | CURIEL, TYLER J.ZHAO, WEIXING WILSON | DARTMOUTH-HITCHCOCK CLINIC, NH | $646,659 | ZRG1 |
| 2022 | Defining the role of histone H3K4 mono-methyltransferase dysfunction in urothelial carcinoma1R01CA265026-01A1 | CHEN, YU | SLOAN-KETTERING INST CAN RESEARCH, NY | $602,303 | MONC |
| 2022 | Blood-based monitoring of bladder-sparing trimodality therapy for muscle-invasive bladder cancer1R01CA259007-01A1 | MIYAMOTO, DAVID T. | MASSACHUSETTS GENERAL HOSPITAL, MA | $597,080 | CONC |
| 2022 | Sexual Dimorphism in Bladder Cancer1R01CA267108-01A1 | LI, XUE SEAN | CEDARS-SINAI MEDICAL CENTER, CA | $577,209 | CG |
| 2022 | NPEPPS is a novel and druggable determinant of chemotherapy resistance in bladder cancer1R01CA268055-01A1 | COSTELLO, JAMES CHRISTOPHERTHEODORESCU, DAN | CEDARS-SINAI MEDICAL CENTER, CA | $518,399 | MCT1 |
| 2022 | Mechanism and Therapeutic Targeting of TRIM29-mediated Invasion in Bladder Cancer1R37CA273138-01 | PALMBOS, PHILLIP L | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $439,943 | TPM |
| 2022 | Targeting Nucleotide Excision Repair Deficiency to Improve Bladder Sparing Treatment for Muscle Invasive Bladder Cancer1R01CA272657-01 | MOUW, KENT W | DANA-FARBER CANCER INST, MA | $432,128 | ZRG1 |
| 2021 | Targeting tumor repopulation and the immune microenvironment to overcome chemoresistance1R01CA255609-01A1 | CHAN, KEITH SYSON | CEDARS-SINAI MEDICAL CENTER, CA | $472,650 | MCT1 |
| 2020 | Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer1R01CA249175-01 | BHARDWAJ, NINAGALSKY, MATTHEWZHU, JUN | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $703,400 | ZRG1 |
| 2020 | Chemotherapy and the Bladder Cancer Immune Microenvironment1R01CA241810-01A1 | KIM, WILLIAM Y.VINCENT, BENJAMIN G | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $566,138 | MCT1 |
| 2020 | eRapa for bladder cancer prevention1R01CA252057-01 | SVATEK, ROBERT SCOTT | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER, TX | $486,532 | CPSS |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.